Aratana nears approval for canine cancer vaccine
Aratana Therapeutics Inc.'s cancer immunotherapy drug for dogs gained a conditional license from the U.S. Department of Agriculture, the company announced Wednesday. To gain full licensure, Aratana (Nasdaq; PETX) will start another field study in early 2018. The vaccine initially will be available for purchase at 12 veterinary oncology practices participating in the study. It's designed to treat dogs with bone cancer after the tumor is surgically removed. It works using listeria, a type of bacteria,…
Publication date: Available online 30 May 2020Source: Pathology - Research and PracticeAuthor(s): Lucero Monterde-Cruz, Eric G. Ramírez-Salazar, Genaro Rico-Martínez, Luis Miguel Linares-González, Roberto Guzmán-González, Ernesto Delgado-Cedillo, Eréndira Estrada-Villaseñor, Margarita Valdés-Flores, Rafael Velázquez-Cruz, A. Hidalgo-Bravo
Publication date: Available online 30 May 2020Source: Gynecologic Oncology ReportsAuthor(s): Shaina Sedighim, Jonathan Burke, Douglas Schneider, Talia Kamdjou, Julio A. Diaz-Perez, Jonathan Trent, Mecker Möller
Publication date: Available online 30 May 2020Source: Comparative Immunology, Microbiology and Infectious DiseasesAuthor(s): Hai Xu, Yale Niu, Weiming Hong, Weixin Liu, Xiaoxin Zuo, Xi Bao, Changming Guo, Yu Lu, Bihua Deng
Publication date: Available online 30 May 2020Source: Comparative Immunology, Microbiology and Infectious DiseasesAuthor(s): Ahmad Erfanmanesh, Arash Ghalyanchilangeroudi, Donya Nikaein, Hossein Hosseini, Tahereh Mohajerfar
Publication date: Available online 30 May 2020Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAuthor(s): Kevin C. Lee, Sung-Kiang Chuang
Publication date: Available online 30 May 2020Source: Pharmacological ResearchAuthor(s): Ling Wang, Ke Deng, Liang Gong, Liang Zhou, Sapna Sayed, Huan Li, Qi Sun, Zijie Su, Zhongyuan Wang, Shanshan Liu, Huifang Zhu, Jiaxing Song, Desheng Lu
(Morris Animal Foundation) Morris Animal Foundation has awarded a $775,000 grant to the University of Pennsylvania to test a vaccine that could improve longevity and quality of life for dogs with the deadly bone tumor, osteosarcoma. The research team will conduct clinical trials to evaluate a novel immunotherapy treatment which combines a molecule expressed by cancer cells with a modified live form of the bacteria Listeria monocytogenes.
CONCLUSIONS: These findings demonstrate that ADXS31-164 administered in the setting of minimal residual disease, can induce HER2/neu specific immunity and may reduce the incidence of metastatic disease and prolong overall survival in a clinically relevant, spontaneous, large animal model of cancer. These findings therefore, have important translational relevance for children with osteosarcoma and adults with other HER2/neu+ cancers. PMID: 26994144 [PubMed - as supplied by publisher]
The purpose of this study is to determine the safety and efficacy of a highly attenuated recombinant Listeria monocytogenes expressing a chimeric human HER2/neu (Lm-LLO-HER2/neu) in combination with palliative radiation (RT) to induce HER2 specific immunity and delay tumor progression in dogs with spontaneous osteosarcoma (OSA). Dogs develop OSA that recapitulates many aspects of human OSA, and are recognized as a clinically relevant, large animal model in which to evaluate novel therapies. Previously we have shown that Lm-LLO-HER2/neu administration to dogs with HER2+ OSA following amputation and chemotherapy is safe, bre...